Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma

European Journal of Haematology

Volumn 82, Issue 3, 2009, Pages 176-183

  Chen, Guanghua ^a   Wang, Yi ^a   Huang, Haiwen ^a   Lin, Fengru ^b   Wu, Depei ^a   Sun, Aining ^a   Chang, Huirong ^a   Feng, Yufeng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

5 azacytidine; Arsenic trioxide; Epigenetics; Methylation; Myeloma; XAF1

Indexed keywords

ARSENIC TRIOXIDE; AZACITIDINE; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN XAF1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXICITY; DNA METHYLATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GEL ELECTROPHORESIS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ARSENICALS; AZACITIDINE; BASE SEQUENCE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA METHYLATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OXIDES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58849157857     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01189.x     Document Type: Article

References (35)

1. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004 9 : 691 704.
2. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997 388 : 300 4.
3. Cillessen S, Reed J, Welsh K, et al. Small-molecule XIAP antagonist restores caspase-9-mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008 1 : 369 75.
4. Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001 3 : 128 33.
5. Fong WG, Liston P, Rajcan E, St. Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XAF1 in cancer cell lines. Genomics 2000 70 : 113 22.
6. Byun DS, Cho K, Ryu BK, et al. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003 63 : 7068 75.
7. Ng KCP, Campos EI, Martinka M, Li G. XAF1 expression is significantly reduced in human melanoma. J Invest Dermatol 2004 123 : 1127 34.
8. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001 98 : 805 13.
9. Hallek M, Bergsagel P, Anderson K. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998 91 : 3 21.
10. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproicacid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007 110 : 2302 8.
11. 3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997 89 : 3345 53.
12. Sciandrello G, Caradonna F, Mauro M, Barbata G. Arsenic-induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004 25 : 413 7.
13. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006 37 : 298 311.
14. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003 101 : 4078 87.
15. Rousselot P, Larghero J, Labaume S, et al. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004 72 : 166 71.
16. Munshi NC, Tricot G, Desikan R, et al. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002 16 : 1835 7.
17. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 2006 91 : 1722 3.
18. Fang X, Liu Z, Fan Y, et al. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer 2006 118 : 2485 9.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 1996 93 : 9821 6.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984 22 : 27 55.
21. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc 2007 2 : 247 50.
22. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004 103 : 20 32.
23. Nizar JB, Jennifer MG, Ileana JM, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002 8 : 3658 68.
24. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res 2003 31 : 5635 43.
25. Singal R, Ginder GD. DNA methylation. Blood 1999 93 : 4059 70.
26. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005 23 : 3971 93.
27. Tasaka T, Asou H, Munker R, et al. Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol 1998 101 : 558 64.
28. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004 103 : 4630 5.
29. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997 89 : 2500 6.
30. Natalia GP, Wee JC, Rebecca FM, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007 109 : 1228 32.
31. Zhao L, Wientjes MG, Au J. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004 10 : 7994 8004.
32. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002 1 : 851 60.
33. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002 100 : 2957 64.
34. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002 21 : 5483 95.
35. Kiziltepe T, Hideshima T, Catley L, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007 6 : 1718 27.